GLPG1690

Status
Phase 2
Condition
Systemic Sclerosis ILD
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

GLPG1690 is a small molecule, selective autotaxin inhibitor which is fully proprietary to Galapagos. Galapagos identified the autotaxin target using its proprietary target discovery platform and developed molecule GLPG1690 as an inhibitor of this target.

Study Purpose

The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis.

Another aim is to find out how safe/well tolerated GLPG1690 will be and whether there are any side effects. The study will also look at other things, including whether the study drug affects disease progression and also if it changes any aspect of the quality of life.

This drug has no clinical trials actively recruiting patients at this time.

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >